Semaglutide (Wegovy / Ozempic) in the UK

What semaglutide is

Semaglutide is a synthetic peptide that mimics the action of GLP-1 (glucagon-like peptide-1), a gut hormone that signals satiety and modulates blood-glucose handling. The molecule has been chemically modified to extend its half-life from a few minutes to about a week, which is why it is dosed once a week as an injection (or, in the oral form, once daily on an empty stomach).

Wegovy vs Ozempic vs Rybelsus

Three brand names, one active ingredient (semaglutide), distinct licensed uses in the UK:

• Wegovy — semaglutide at higher dose, licensed for chronic weight management in eligible adults under specific clinical criteria.
• Ozempic — semaglutide at lower dose, licensed for type 2 diabetes.
• Rybelsus — oral semaglutide, licensed for type 2 diabetes.

The molecule is the same; the regulatory indication and dose schedule differ. A prescriber chooses based on the clinical reason, not the patient's preference for the brand.

UK access — the lawful routes

1. NHS via a tier-3 weight-management service or specialist referral — eligibility is restrictive and depends on current NICE guidance and local commissioning. Ask your GP whether you meet criteria; expect a wait.
2. NHS via diabetes services — for type 2 diabetes indications.
3. Private prescription from a UK-registered prescriber (GP, specialist, or appropriately-registered private prescriber), dispensed by a UK-regulated pharmacy. This route is lawful when done correctly; quality of online services varies a lot.

Any other route — social-media sellers, "research only" semaglutide vials, untraceable EU shipments — sits outside the regulated system. The risks are detailed under fake weight-loss pens and online seller red flags.

How a good private service looks

• An actual clinical consultation with a UK-registered prescriber — not a 60-second tick-box form.
• The prescriber asks about contraindications: personal or family history of medullary thyroid cancer, MEN2, pancreatitis, severe gastrointestinal conditions, pregnancy / breastfeeding, and current medications.
• A dose-titration plan — semaglutide is typically started at a low dose and increased over weeks to manage gastrointestinal side effects.
• Dispensed by a UK pharmacy listed on the GPhC or PSNI register, in UK packaging with a Patient Information Leaflet.
• Ongoing access to the prescriber for side-effect questions and review intervals.

See private clinics — what good looks like for a longer checklist.

What semaglutide actually does in practice

• Slows gastric emptying — food sits in the stomach longer, which is most of the reason people feel less hungry and eat less per meal.
• Acts on hypothalamic appetite centres — reduces drive to eat between meals.
• Increases glucose-dependent insulin secretion — primarily relevant for type 2 diabetes outcomes.
• Average weight loss in the STEP trials (Wegovy 2.4mg) was around 15% of body weight at 68 weeks, with substantial individual variation — some lose much more, some much less.

What semaglutide is not

• Not a substitute for resistance training or dietary structure during the loss phase — lean-mass loss is a known concern.
• Not a "one course" treatment — obesity is generally chronic; stopping is associated with weight regain in trial data.
• Not appropriate for everyone — contraindications and prescriber-led suitability assessment matter.